Skip to main content
BHC
NYSE Life Sciences

Bausch Health 10-Q Details $1.43B Salix Impairment, $643M Note Redemption and New $50M Buyback

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$7.56
Mkt Cap
$2.588B
52W Low
$4.33
52W High
$8
52W Position info
75% above low
Off High info
5.5% below high
Rel. Volume info
2.6× avg
Market data snapshot near publication time

BHC sits 75% above its 52-week low of $4.33 on elevated volume (2.6× avg).

Summary

Bausch Health's Q3 10-Q confirms the October 28 earnings beat and discloses a $1,426 million Salix goodwill impairment, $1,714 million of nine-month operating cash flow, a $643 million note redemption and a new $50 million buyback.


Key Events · Earnings and Guidance · BHC

  • Q3 Earnings Confirmed in Full 10-Q

    Q3 2026 revenue was $2,941 million, up 10% from $2,681 million, and net income attributable to Bausch Health was $436 million, or $1.16 per basic share, versus $179 million ($0.48) a year earlier.

  • $1.43B Salix Goodwill Impairment

    A $1,426 million non-cash goodwill impairment on the Salix reporting unit, triggered by the January 2026 failure of two rifaximin Phase 3 trials, drove a nine-month net loss of $729 million, or $(1.95) per share.

  • Cash Build Funds Debt Paydown

    Nine-month operating cash flow was $1,714 million versus $905 million a year earlier, lifting cash and equivalents to $2,485 million from $1,309 million at December 31, 2025.

  • $643M Notes to Be Redeemed

    Bausch Health Americas will redeem all $643 million of 8.500% Senior Notes due 2027 on November 30, 2026 using cash on hand, terminating that indenture.


Analysis · BHC · Life Sciences

The headline Q3 beat was already out on October 28, but the full 10-Q carries the balance-sheet story. A $1,426 million non-cash goodwill impairment on the Salix unit, triggered by the January 2026 rifaximin Phase 3 failures, pushed the nine-month result to a $729 million net loss, even as Q3 net income rose to $436 million. Cash generation is the offset: $1,714 million of operating cash flow in nine months lifted cash to $2,485 million, enough to fund the announced redemption of all $643 million of 8.500% notes due 2027 from cash on hand and to support a new $50 million buyback. Debt remains the constraint at $20,168 million principal, with $3,766 million maturing in 2028 and Xifaxan generic entry expected in 2028.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, BHC was trading at $7.56 on NYSE in the Life Sciences sector, with a market capitalization of approximately $2.6B. The 52-week trading range was $4.33 to $8.00. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BHC - Latest Insights

BHC
Oct 28, 2026, 4:07 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $8.25
Real-time Price: $8.33 info
Change: +$0.080 (+0.97%) info
Market Cap: $3.125B info
BHC
Oct 28, 2026, 4:01 PM EDT
Source: PR Newswire
Importance Score:
8
Price at Filing: $6.92
Real-time Price: $8.33 info
Change: +$1.41 (+20%) info
Market Cap: $3.125B info
BHC
Jul 29, 2026, 4:11 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.85
Real-time Price: $8.33 info
Change: +$3.49 (+72%) info
Market Cap: $3.125B info
BHC
Jul 29, 2026, 4:05 PM EDT
Source: PR Newswire
Importance Score:
8
Price at Filing: $4.90
Real-time Price: $8.33 info
Change: +$3.43 (+70%) info
Market Cap: $3.125B info
BHC
Apr 29, 2026, 6:12 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $5.63
Real-time Price: $8.33 info
Change: +$2.70 (+48%) info
Market Cap: $3.125B info